Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06451588
Other study ID # 537025
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date June 1, 2024
Est. completion date March 2026

Study information

Verified date June 2024
Source University Hospital of North Norway
Contact Gunnstein Bakland, MD PhD
Phone +4795860791
Email gunnstein.bakland@unn.no
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Although biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints. It has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gut compared to healthy controls, and that this correlates to disease activity and respons to therapy. The goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of biologic therapy. The main questions it aims to answer are: - Can FMT reduce disease activity in axial SpA? - Can FMT alleviate pain and reduce fatigue in axial SpA? - Is the composition of microorganisms restored to normal in patients with SpA after a treatment with FMT? Participants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline. The primary endpoint will be evaluated after 90 days, but efficacy and safety will be monitored from baseline until 365 days.


Description:

Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease affecting the sacroiliac joints (SIJ) and the spine. The approach to treatment of axSpA is a combination of patient education, with a focus on exercise and lifestyle, and a medical treatment. Non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line medical treatment, providing symptom relief for a large portion of the patients. For patients with inadequate response, or intolerance, to NSAIDs, biological (TNFi and IL17i) or targeted synthetic (JAKi) disease modifying drugs (b/ts-DMARDs) are considered a second-line treatment option and provide excellent efficacy for many patients. However, a substantial portion of the patients experience active disease despite this second-line therapy. The cause of the disease is multifactorial, and both genetic and environmental factors contribute in the pathogenesis. Patients with axSpA have a higher prevalence of inflammatory bowel disease (IBD) than the background population, i.e. Crohn's disease and ulcerative colitis. However, inflammation in the gut is also demonstrated in 50-70% of patients without symptoms of IBD, and this inflammation is believed to be of importance in the development of the disease. The human gut microbiota is the collection of microbes in the intestines. The composition of the microbiota is the result of many factors and have evolved over time to form a mutually beneficial relationship to both humans and microorganisms. Normally there is a balance and a stability in this composition, but in many conditions an imbalance, termed dysbiosis, has been demonstrated. This is also the case in axSpA, and the extent of this dysbiosis also relates to disease activity and to response to therapy. Fecal microbiota transplantation (FMT) is a method used to alter the microbiota composition by transferring microbes from a healthy individual to a recipient. In several conditions this has both proven the ability to alter the microbiota and to provide symptom relief , e.g. clostridium difficile infections, ulcerative colitis and irritable bowel syndrome. Given the potential role of the microbiota in the pathogenesis of axSpA, we wish to evaluate whether replacing the microbiota in patients with inadequate response to biologic therapy with FMT can be efficacious in providing a state of inactive disease and symptom relief.


Recruitment information / eligibility

Status Recruiting
Enrollment 99
Est. completion date March 2026
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Axial Spondyloarthritis according to the ASAS classification criteria - Active disease defined as ASDAS =2.1 with elevated CRP =4 OR active inflammation on MRI within the last 3 months - Onset of axial SpA within last 10 years - Unsatisfactory relief of NSAIDs - On stable immunomodulatory treatment (TNFi, IL17i or JAKi) the last 3 months Exclusion Criteria: - Planned dose adjustment or change in immunomodulatory treatment the next 90 days - Disease or disorder with life expectancy of =5 years - Severe immune deficiency (acquired, congenital og du to medication) - Previous treatment with FMT - Regular use of opioids with the exception of codeine and tramadol - Any specific diagnosis that could explain or contribute to the patients back pain (e.g. tumor, fracture, infection or degenerative disease) - Inflammatory spinal disease other than axSpA - Severe psychiatric disorder, alcohol- or drug abuse - Active inflammatory bowel disease - Microscopic colitis, diverticulitis or ileus - Active psoriasis - Fibromyalgia - Abdominal surgery excluding appendectomy, cholecystectomy, hysterectomy, caesarian section, sapling-ooforectomy and hernia surgery - Malignant disease excluding basalioma and melanoma stage 1 - Conditions with expected necessary treatment with antibiotics during the study period, e.g. periodontitis end ischemic digital ulcers - Treatment with antibiotics 12 weeks prior to study entry - Pregnancy, lactation or planned pregnancy within the next 3 months - Contraindications for rectal catheter insertion - Planned rehabilitation program the next 90 days - Limited ability to comply with protocol requirements, including biobank participation

Study Design


Intervention

Drug:
FMT
Active FMT
Placebo
The placebo treatment will be prepared based on the patients' fecal samples (autologous).

Locations

Country Name City State
Norway University Hospital North Norway Tromsø

Sponsors (2)

Lead Sponsor Collaborator
University Hospital of North Norway Helse Nord

Country where clinical trial is conducted

Norway, 

References & Publications (6)

Baraliakos X, Braun J. Spondyloarthritides. Best Pract Res Clin Rheumatol. 2011 Dec;25(6):825-42. doi: 10.1016/j.berh.2011.11.006. — View Citation

Bazin T, Hooks KB, Barnetche T, Truchetet ME, Enaud R, Richez C, Dougados M, Hubert C, Barre A, Nikolski M, Schaeverbeke T. Microbiota Composition May Predict Anti-Tnf Alpha Response in Spondyloarthritis Patients: an Exploratory Study. Sci Rep. 2018 Apr 3 — View Citation

Breban M, Beaufrere M, Glatigny S. The microbiome in spondyloarthritis. Best Pract Res Clin Rheumatol. 2019 Dec;33(6):101495. doi: 10.1016/j.berh.2020.101495. Epub 2020 Mar 12. — View Citation

Imdad A, Nicholson MR, Tanner-Smith EE, Zackular JP, Gomez-Duarte OG, Beaulieu DB, Acra S. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database Syst Rev. 2018 Nov 13;11(11):CD012774. doi: 10.1002/14651858.CD012774.pub2. — View Citation

Johnsen PH, Hilpusch F, Cavanagh JP, Leikanger IS, Kolstad C, Valle PC, Goll R. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre — View Citation

Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020 Jun;30(6):492-506. doi: 10.1038/s41422-020-0332-7. Epub 2020 May 20. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory endpoint Changes in taxonomy and function of the microbiome, the immune system, metabolome and gut epithelial barrier in participants with vs without treatment success to dFMT and aFMT baseline and day 90
Other Exploratory endpoint Differences in baseline taxonomy and function of the microbiome, the immune system, metabolome and gut epithelial barrier in participants with vs without treatment success to dFMT and aFMT baseline
Primary Minimal Clinically Important Improvement Proportion of patients that meet the criteria of Minimal Clinically Important Improvement in the donor FMT (dFMT) versus the autologous FMT (aFMT) group at day 90 after treatment. Minimal Clinically Important Improvement is defined by a decrease of =1,1 in ASDAS-CRP 90 days
Secondary Adverse events The proportion of patients experiencing any adverse events from baseline util day 90 and day 365 Day 0-90 and day 91-365
Secondary Ankylosing Spondylitis Disease Activity Score (ASDAS)20 Change in the dFMT vs aFMT group from baseline baseline, day 30, day 60 and day 90
Secondary Bath Ankylosing Spondylitis Disease Activity Index Change in the dFMT vs aFMT group from baseline baseline, day 30, day 60 and day 90
Secondary Bath Anykylosing Spondylitis Funtional Index Change in the dFMT vs aFMT group from baseline baseline, day 30, day 60 and day 90
Secondary Patient global assessment Change in the dFMT vs aFMT group from baseline baseline, day 30, day 60 and day 90
Secondary VAS spinal pain Change in the dFMT vs aFMT group from baseline baseline, day 30, day 60 and day 90
Secondary Modified Fatigue Impact Scale Change in the dFMT vs aFMT group from baseline baseline and day 90
Secondary RAND-36 Change in the dFMT vs aFMT group from baseline baseline and day 90
Secondary Maastricht Ankylosing Spondylitis Enthesitis Score Change in the dFMT vs aFMT group from baseline baseline and day 90
Secondary The 66/68 Joint Count Score Change in the dFMT vs aFMT group from baseline baseline and day 90
Secondary Bath Ankylosing Spondylitis Metrology Index Change in the dFMT vs aFMT group from baseline baseline and day 90
Secondary Ankylosing Spondylitis Disease Activity Score (ASDAS)40 Long term change that includes the extended open labeled follow up in the dFMT vs aFMT group from baseline baseline and day 30, day 60, day 90, day 180, day 270 and day 365
Secondary Bath Ankylosing Spondylitis Disease Activity Index Long term change that includes the extended open labeled follow up in the dFMT vs aFMT group from baseline baseline and day 30, day 60, day 90, day 180, day 270 and day 365
Secondary Bath Anykylosing Spondylitis Funtional Index Long term change that includes the extended open labeled follow up in the dFMT vs aFMT group from baseline baseline and day 30, day 60, day 90, day 180, day 270 and day 365
Secondary Patient global assessment Long term change that includes the extended open labeled follow up in the dFMT vs aFMT group from baseline baseline and day 30, day 60, day 90, day 180, day 270 and day 365
Secondary VAS spinal pain Long term change that includes the extended open labeled follow up in the dFMT vs aFMT group from baseline baseline and day 30, day 60, day 90, day 180, day 270 and day 365
Secondary Modified Fatigue Impact Scale Long term change that includes the extended open labeled follow up in the dFMT vs aFMT group from baseline baseline and day 30, day 60, day 90, day 180, day 270 and day 365
Secondary RAND-36 Long term change that includes the extended open labeled follow up in the dFMT vs aFMT group from baseline baseline and day 30, day 60, day 90, day 180, day 270 and day 365
See also
  Status Clinical Trial Phase
Terminated NCT02685904 - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis Phase 3
Completed NCT02186873 - A Study of Golimumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT01668004 - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Phase 4
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01934933 - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Phase 4
Not yet recruiting NCT04875299 - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed NCT02758782 - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Phase 4
Completed NCT02763111 - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis Phase 2
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT01750528 - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis N/A
Completed NCT01463189 - Web-based Support to Manage Arthritis Pain Phase 2
Completed NCT01091675 - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs Phase 3
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Recruiting NCT00747578 - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan N/A
Completed NCT00715091 - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Phase 4
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00367211 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Phase 3
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4